Dr. Tirso Mark Lara, MD

Dr. Lara practices at Fort Lauderdale Eye Institute in Plantation, Florida.

Dr. Lara's NPI, 1457353054, was assigned on August 12, 2005. Dr. Lara graduated from Universidad La Salle School of Medicine in 1994. Dr. Lara holds Florida license ME93684.

Dr. Lara's primary practice is Fort Lauderdale Eye Institute, at 850 S Pine Island Rd, Plantation, FL 33324 in Broward County. The practice phone is (954) 741-5555.

Dr. Lara's primary practice is Fort Lauderdale Eye Institute in Plantation, Florida. Dr. Lara is also affiliated with Broward Health Imperial Point. Dmand AI also links Dr. Lara to 3 more medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lara practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Lara's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Lara is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Lara's licenses on file in 2 states: Florida and Alabama.

Dmand AI lists age-related macular degeneration, cataract, eyelid inflammation, glaucoma, hypertensive retinopathy, laser destruction of retinal or choroid lesions, retinal detachment and retinal occlusion among the conditions Dr. Lara treats.

CMS data shows 75,360 Medicare services from Dr. Lara across 20 procedure codes in 2024, for 402 Medicare patients. Medicare paid $1,330,625 for them. Every service was in an office.

CMS counts 402 Medicare patients who saw Dr. Lara in 2024. The largest group is 65 to 74, with 154 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 1.59, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lara's median patient age at 70, with 53% women.

In 2024, Dr. Lara wrote 279 Medicare Part D claims for 99 patients. 38% of them were for generic drugs. CMS names the drug for 200 of them, across 8 drugs with 11 or more claims each, at $29,588 in total drug cost. In 2023, CMS named 174 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Lara for performance year 2024, reported individually. Dr. Lara accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Lara to 1 clinical trial. Conditions studied include Macular Degeneration and Retinal Degeneration. Open Payments lists research payments to Dr. Lara that name 1 trial.

CMS Open Payments shows 215 general payments to Dr. Lara from 32 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 44% of the total. OnMark, Inc. paid the most, $5,656. It also lists 8 research payments totaling $1,520 in 2019, naming 1 clinical trial.

Dr. Lara graduated from Universidad La Salle School of Medicine in 1994.

Dr. Lara is in network with 18 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.